The early formation and the variety of the tumor morphology, as well as the potent metastatic ability seen in the Ela-myc and MT-tgfα/Ela-myc transgenic mice, make them good animal models for testing new therapeutic and preventive regimens or agents for the management of pancreatic cancer. This evidence concerns the gene TGFA and familial pancreatic carcinoma.